ReportGem ReportGem

U.S. COMPANY FILING

AMGEN INC — Form 10-K filed 2026-02-13

Filed: 2026-02-13Company: AMGEN INCTicker: AMGNExchange: NasdaqForm: 10-KReport period: 2025-12-31SEC accession: 0000318154-26-000010Event: earningsMateriality: 85

Filing text preview

Amgen's 2025 product sales grew 10% to $35.15 billion, driven by 13% volume growth. Operating cash flow was $10.0 billion, debt reduced by $6.0 billion, and quarterly dividend increased 6% to $2.38 per share. Risks include tariffs, tax law changes, and litigation.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-02-1310-Q2026-08-05 · 10-Q8-K2026-07-31 · 8-K10-Q2026-05-01 · 10-Q10-Q2025-11-05 · 10-Q